Prostate cancer prospects dashed for Takeda's orteronel
This article was originally published in Scrip
Executive Summary
Hopes have faded for Takeda's orteronel in prostate cancer after it failed to meet the all-important primary endpoint of overall survival (OS) in the ELM-PC4 pivotal Phase III trial. The drug was shown to reduce the risk of radiographic progression free survival (rPFS), the other primary endpoint.